News Conference News AHA 2016 Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding Shelley Wood November 21, 2016
News Conference News AHA 2016 Errar la Dosis de NOAC en la Práctica Clínica Diaria es algo Habitual, lo cual tiene Implicaciones en Materia de ACV y Hemorragias Shelley Wood November 21, 2016
News Daily News Questions Over Risk-Benefit Balance for IVC Filters Still Vex Clinicians Caitlin E. Cox November 17, 2016
News Daily News Las Dudas en torno al Equilibrio Riesgos-Beneficios para los Filtros VCI Siguen Irritando a los Médicos Caitlin E. Cox November 17, 2016
News Conference News AHA 2016 Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results Todd Neale November 15, 2016
News Conference News AHA 2016 Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI Todd Neale November 14, 2016
News Daily News Registry Data Show Rise and Fall of Bivalirudin vs Heparin for Primary PCI Yael L. Maxwell November 11, 2016
News Daily News Datos de Registro Revelan el Ascenso y Caída de la Bivalirudina frente a la Heparina en la Realización de PCI Primarias Yael L. Maxwell November 11, 2016
News Conference News AHA 2016 AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR Shelley Wood November 09, 2016
Presentation TCT 2016 Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure? Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White November 01, 2016
News Industry News TCT 2016 Long-Term Study Results Show that PFO Closure is More Effective Than Medical Management in Preventing Recurrent Stroke November 01, 2016
Presentation TCT 2016 When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy? Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran November 01, 2016
Presentation TCT 2016 Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding Presenter: David P. Faxon, C. Michael Gibson November 01, 2016
Presentation TCT 2016 What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt November 01, 2016
Presentation TCT 2016 The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger November 01, 2016
News Conference News TCT 2016 Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI Yael L. Maxwell October 31, 2016
Presentation TCT 2016 Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven? Presenter: Vivek Y. Reddy, Steven J. Yakubov, David R. Holmes Jr. October 30, 2016
Presentation TCT 2016 Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness) Presenter: Vivek Y. Reddy, Steven J. Yakubov October 30, 2016
Presentation TCT 2016 Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI! Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White October 30, 2016
Presentation TCT 2016 Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI! Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo October 30, 2016